Colchicine (Colcrys®) + placebo + allopurinol
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Intercritical Gout
Conditions
Intercritical Gout
Trial Timeline
Oct 1, 2011 → Sep 1, 2012
NCT ID
NCT01451645About Colchicine (Colcrys®) + placebo + allopurinol
Colchicine (Colcrys®) + placebo + allopurinol is a approved stage product being developed by Regeneron Pharmaceuticals for Intercritical Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT01451645. Target conditions include Intercritical Gout.
What happened to similar drugs?
0 of 1 similar drugs in Intercritical Gout were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01451645 | Approved | Completed |
Competing Products
1 competing product in Intercritical Gout
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rilonacept 80 mg + Rilonacept 160 mg | Regeneron Pharmaceuticals | Phase 3 | 40 |